EQL Pharma AB (publ) (STO:EQL)
Sweden
· Delayed Price · Currency is SEK 82.90
+0.80 (0.97%)
At close: May 12, 2025
EQL Pharma AB Revenue
In the fiscal year ending March 31, 2025, EQL Pharma AB had annual revenue of 373.52M SEK with 41.39% growth. EQL Pharma AB had revenue of 113.26M in the quarter ending March 31, 2025, with 44.95% growth.
Revenue
373.52M
Revenue Growth
+41.39%
P/S Ratio
6.45
Revenue / Employee
13.34M
Employees
21
Market Cap
2.41B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2025 | 373.52M | 109.35M | 41.39% |
| Mar 31, 2024 | 264.17M | 4.26M | 1.64% |
| Mar 31, 2023 | 259.91M | -149.84M | -36.57% |
| Mar 31, 2022 | 409.75M | 230.61M | 128.73% |
| Mar 31, 2021 | 179.14M | 107.11M | 148.70% |
| Mar 31, 2020 | Pro | Pro | Pro |
| Mar 31, 2019 | Pro | Pro | Pro |
| Mar 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Swedish Orphan Biovitrum AB | 26.24B |
| Sectra AB | 3.30B |
| Getinge AB | 35.57B |
| Camurus AB | 1.87B |
| Medicover AB | 23.56B |
| AddLife AB | 10.42B |
| Vitrolife AB | 3.61B |
| Vimian Group AB | 4.24B |